S&P 500 All time high of $39.55 May 13th, 2014 Page 8 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 9 Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Page 10 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Page 13 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment Page 14 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? Platform operating income mix percentage 2005Y* 2008Y* 2010Y* 2013Y 2014 Q1 Global Specialty Engineered Materials $ 0.4 $ 17.6 $ 49.7 $ 57.2 $ 18.3 Global Color, Additives and Inks 4.3 28.1 37.7 104.0 30.4 Designed Structures and Solutions - - - 33.4 11.2 Specialty Platform $ 4.7 $ 45.7 $ 87.4 $ 194.6 $ 59.9 Performance Products and Solutions 75.7 31.3 54.0 56.0 16.0 Distribution 19.5 28.1 42.0 63.3 17.2 SunBelt Joint venture 91.9 28.6 18.9 - - Corporate (51.5) (425.1) (27.7) (82.4) (36.7) Operating income (loss) GAAP $ 140.3 $ (291.4) $ 174.6 $ 231.5 $ 56.4 Less: Corporate operating expense 51.5 425.1 27.7 82.4 36.7 Operating income excluding Corporate $ 191.8 $ 133.7 $ 202.3 $ 313.9 $ 93.1 Specialty platform operating mix percentage 2% 34% 43% 62% 64% * Historical results include the Resin and Specialty Coatings businesses within the Performance Products and Solutions segment.

These conditions can be defined and agreed at a trial stage and under the consultation of a ColorMatrix Technical Service Engineer.

Gravi-Tech™ BIO Bio-Based Formulations Gravi-Tech™ BIO bio-based formulations are density modified engineered polymers that contain partially bio-based resin from renewable plant sources.

ColorMatrix’s Triple A™ scavenging technology is engineered to minimize and control AA levels during PET processing and during the life of the product.

Toner make-up tanks should be placed conveniently close to the addition point in the PET production process and vessels, and pipework and ancillary equipment should be sized according to good practice engineering principles and in accordance with desired batch make up frequencies (related to plant size and production throughput).

These engineered TPEs also have the added benefit of eliminating secondary processing, which reduces energy use and supports manufacturers in reaching their sustainability goals.

MEDICAL DEVICE DISINFECTION—HOW TO PREVENT CRACKING AND CRAZING Understanding polymer performance is key to minimizing disinfectant-related failures DISINFECTANT-RELATED DAMAGE ON POLYMER HOUSINGS Strong chemicals used to reduce hospital- acquired infections can damage equipment and result in material failures, such as: • Stress cracking • Crazing • Discoloration CHEMICAL RESISTANCE REQUIREMENTS VARY BY ENVIRONMENT • Patient/exam rooms • Operating and radiology rooms • Reception areas • Home (patient equipment & devices) Healthcare devices must perform flawlessly in a myriad of challenging environments and engineers must be certain their devices can withstand increasingly potent disinfectants, which have begun to outstrip the performance of traditional polymers.

Environment When used in an industrial setting, ATO is typically handled using engineered systems designed to control releases from the facility.

RESILIENCE™ HC OUTPERFORMS COMPETING POLYMERS Design engineers are increasingly looking more frequently for better chemical resistance properties in rigid device housings to combat the effects of disinfectants.

Vi måste behandla konfidentiell information från tredje part med samma försiktighetsåtgärder som för vår egen information. För transparens ska gåvor till tredje parter kodas som ”gåva till tredje part” i Concur. Du bör alltid vara uppmärksam och observant på en tredje parts beteende när du gör affärer med dem.